Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Treasury Shares (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Treasury Shares for 17 consecutive years, with $43.6 billion as the latest value for Q4 2025.

  • Quarterly Treasury Shares changed 0.17% to $43.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.6 billion through Dec 2025, changed 0.17% year-over-year, with the annual reading at $43.6 billion for FY2025, 0.17% changed from the prior year.
  • Treasury Shares for Q4 2025 was $887.0 million at Bristol Myers Squibb, roughly flat from $887.0 million in the prior quarter.
  • The five-year high for Treasury Shares was $896.0 million in Q1 2024, with the low at $7.0 million in Q3 2021.
  • Average Treasury Shares over 5 years is $611.0 million, with a median of $824.0 million recorded in 2022.
  • The sharpest move saw Treasury Shares rose 29.37% in 2022, then decreased 0.25% in 2024.
  • Over 5 years, Treasury Shares stood at $31.3 billion in 2021, then grew by 23.54% to $38.6 billion in 2022, then rose by 13.33% to $43.8 billion in 2023, then decreased by 0.25% to $43.7 billion in 2024, then dropped by 0.17% to $43.6 billion in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $43.6 billion, $43.6 billion, and $43.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.